Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg ups Kingfisher target price but keeps at 'hold'

(Sharecast News) - Berenberg has raised its target price for Kingfisher shares from 306p to 331p following the retailer's first-half results, but kept a 'hold' rating on the stock. DIY retailer Kingfisher upgraded its adjusted pre-tax profit guidance for the year to January 2026 by 6% following a 13% beat to consensus forecasts with its interim results.

"The beat and upgrade were primarily driven by a stronger-than-anticipated gross margin, while the upside surprise in Q2 sales trends was much less significant," Berenberg said.

The broker highlighted that the Kingfisher's gross margins - while still low at around 38% - are set to rise further over the coming 18 months, helped in part by a weaker US dollar, supplier negotiations, warehousing reduction, AI-refined pricing/promotions and the growth of a high-margin marketplace sales and retail media business.

Berenberg said that, following three years of negative like-for-like sales trends, the first half of this year saw "some signs of a sales turnaround", with the UK DIY market improving and negative conditions in France easing slightly.

The stock was flat at 289.2p by 1141 BST on Wednesday, having jumped 15% the previous session, leaving limited upside (around 14%) to Berenberg's new target price.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.